EECP History 2017-06-28T17:09:47+00:00

EECP History & Timeline

EECP Timeline

1950

Hydraulic Counterpulsation

Harken and Associates and Birtwell developed the first counterpulsation technology at Harvard University. Counterpulsation techniques featured hydraulic compression. With technological advancements, pneumatic cuffs were invented that revolutionized counterpulsation therapy.

1960

EECP Continued to Evolve

Several scientists evolved counterpulsation to a noninvasive technique using a primitive external device that applied pressure generated by a hydraulic system. Studies with early non-invasive machines demonstrated the potential to increase survival in patients with myocardial infarction, cardiogenic shock and angina pectoris. Pneumatic devices soon replaced the cumbersome hydraulic machines.

1968

National Institutes of Health

Scientists at the National Institutes of Health suggested enhanced results due to the sequential pulsation of blood from the extremities rather than the non-sequenced pulsation being used by hydraulic machines.

1970

China Helps Perfect EECP

Zheng and colleagues at Sun Yat Sen University in China reported studies with a newly designed sequenced pulsation system using four sets of compression bladders on the patient’s legs, buttocks and arms. In these trials, effects of the sequenced system were studied in patients with angina pectoris and acute myocardial infarction. In more than 90..Read More

1972

The U.S. FDA approved EECP

The U.S. FDA approved EECP for treatment of cardiogenic shock and myocardial infarction (heart attack).

1980

China Engages More with EECP

China began developing extensive technological advancements with EECP and continues to make positive strides.

1989

SUNY-Stony Brook Research

Researchers from the State University of New York at Stony Brook determined that enhanced external counterpulsation continued to show helpful effects on patients even three years after treatment.

1995

EECP was cleared by the FDA for angina pectoris.

EECP was cleared by the FDA for angina pectoris.

The Health Care Financing Administration (HCFA)

The Health Care Financing Administration (HCFA) denied Vasomedical, Inc.’s, manufacturer of EECP technology, application to approve EECP for angina. The given reason was that HCFA required a double-blind clinical study and publication of research in peer-review journals.

1996

Sara Soulati enters the field of EECP

Sara Soulati began to study EECP for cardiovascular disease reversal and prevention as well as the effect of EECP on elite athletes.

1997

Sara Soulati studies EECP and Sports

Sara Soulati launched studies in EECP and sports and helped a variety of elite athletes with recovery time, speed and endurance.

1998

Vasomedical MUST Trial

Vasomedical presented to HCFA results of its Multicenter Study of EECP (MUST Trial) featuring seven medical centers and 139 patients in a double-blind study relating to Class I, II and III angina. HCFA’s Grant Bagley, MD, director of HCFA Coverage and Analysis, again denied coverage stating results of the MUST Trial needed to be published..Read More

1999

CMS & EECP

After CMS failed to approve EECP for angina again, Wallace Haselton, a former member of Vasomedical’s board of directors, went head-to-head with HCFA to secure coverage of EECP for angina. He called Senator Edward Kennedy (D-Mass.), and together they petitioned the Senate Finance Committee, regulators, legislators and anyone they could enlist to help change the..Read More

2000

EECP Approved by CMS

(five years after the FDA), Grant Bagley, MD, finally approved EECP for reimbursement, BUT only for these advanced conditions: Canadian Class III or class IV angina (FDA approval is for Canadian Class I, II, III, IV angina) A person’s condition is inoperable or at high risk of operative complications or post-operative failure. A person’s coronary..Read More

EECP to ECP

HCFA changed all references of EECP to ECP in written materials. These coverage guidelines issued by HCFA went unchallenged by the medical industry or manufacturers of EECP technology. These limited coverage guidelines remain in force today.

2002

The American Heart Association

The American Heart Association and the American College of Cardiology issued guidelines on treating angina stating that more studies are required on EECP before it can be recommended as a standard treatment for angina. So far, EECP has not been widely accepted in clinical practice.

Sara Soulati launches Global Cardio Care

Sara Soulati launches Global Cardio Care, Inc. in Inglewood, California in the heart of the African-American community.

The FDA approved EECP for treatment of congestive heart failure.

The FDA approved EECP for treatment of congestive heart failure.

2004

EECP Benefits

Several studies also found that EECP shows some benefit for patients with stabilized heart failure.

2005

Vasomedical & PEECH Trial

Vasomedical released results of its Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure (PEECH) study for congestive heart failure and published results in a peer-review journal. This study found that patients with mid- to moderate-severe heart failure experienced an improvement in their New York Heart Association (NYHA) class after counterpulsation. However, the long-term..Read More

CMS Denies Vasomedical

CMS denied the request by Vasomedical to approve Medicaid reimbursement of EECP for congestive heart failure, advanced stages of angina, cardiogenic shock or coronary artery disease.

Clinical Research Continues

Clinical researchers have continued to publish studies on the efficacy of EECP in support of disease treatment.

2006

Sara Soulati perfects the Sara Soulati Health for Life Program

Sara Soulati perfects the Sara Soulati Health for Life Program, a lifestyle medicine program based on plant-based nutrition to prevent and reverse cardiovascular disease

2010

“EECP is a Regenerative Therapy”

“EECP is a Regenerative Therapy,” published in Frontiers in Bioscience magazine, clinical researchers from Texas A&M Health Science Center College of Medicine and Cardiology showed that EECP therapy is likely to regenerate circulatory stem cells of diseased organs in the body.

2012

Sara Soulati opens Global Cardio Care-West Los Angeles.

Sara Soulati opens Global Cardio Care-West Los Angeles.

2013

FDA Cardiology Committee

The FDA cardiology committee met to review external counterpulsation. They decided that EECP/ECP had been proven safe and effective in the treatment of refractory angina with patients in clinical studies to lower the classification from Class III to Class II. This permits EECP/ECP devices to be regulated under the 510(k) regulations.

2014

Sara Soulati applies for a patent

Sara Soulati applies for a patent for the Sara Soulati Health for Life Program

Sign up Today for
a Free EECP Session

Call us today at
310.412.8181 (Inglewood)
310.473.3030 (West LA)

EECP is FDA cleared for the following conditions: angina pectoris, congestive heart failure, cardiogenic shock, and acute myocardial infarction.
Other diseases or conditions mentioned have been studied in clinical trials. Clinical research shows there is, in fact, improvement in these disease types with EECP treatment. Please consult your physician. All patients are treated at Global Cardio Care Centers, Ronald Seymour Weaver, M.D. Inc., a medical corporation. Global Cardio Care Centers is an independent outpatient EECP center. All results and health outcomes are a combination of the patent-pending Sara Soulati Health For Life Program™ and Sara Soulati EECP® Method offered exclusively at Global Cardio Care Centers and Global Cardio Care — West Los Angeles.